Study S001269

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

ClinicalTrials.gov record

Registration

Registration: NCT06221969
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 1024
Start: 2024-01-16
Primary completion: 2026-03-04
Lead sponsor: Novo Nordisk A/S
Conditions: Type 2 Diabetes
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1282-5561; OTHER:2023-503789-21-00; NIH:2023

Registered primary outcomes

Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 68)]
Relative change in body weight [From baseline (week 0) to end of treatment (week 68)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.